Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia
暂无分享,去创建一个
M. Béné | C. Récher | N. Ifrah | J. Delaunay | N. Vey | I. Luquet | D. Bouscary | P. Guardiola | F. Dreyfus | E. Jourdan | J. Harousseau | M. Escoffre-Barbe | M. Hunault | B. Lioure | J. Cahn | C. Bonmati | Edouard Randriamalala | D. Guyotat | A. Pigneux | N. Fegueux | S. Lissandre | R. Guiéze | M. Ojeda-Uribe | M. Escoffre‐Barbe | R. Guièze | M. Escoffre-barbe
[1] J. Ouyang,et al. Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia , 2013, PloS one.
[2] J. Beyene,et al. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysis , 2013, British journal of haematology.
[3] H. Dombret,et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Chevallier,et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. , 2012, Blood.
[5] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[6] Augustin Ferrant,et al. Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.
[7] T. Naoe,et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.
[8] M. Bernard,et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial , 2010, Leukemia.
[9] J. Bennett,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[10] M. Vignetti,et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[12] J. Rowe. Optimal induction and post-remission therapy for AML in first remission. , 2009, Hematology. American Society of Hematology. Education Program.
[13] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[14] T. H. A. C. O. G. Roup. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998 .
[15] R. Peto,et al. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998, British journal of haematology.
[16] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .